products, 2 nasal products, 2 oral products, and 2 sterile ophthalmics), manufacturing, and regulatory affairs (specifically as it relates to electronic submissions). CUSTOpharm filed the first eCTD ANDA with the FDA in 2004, have filed over 170 ANDA's since. This background allows us to visualize the "big picture" of their clients' projects with a marketable finished product as the ultimate goal. This "big picture" approach places CUSTOpharm ahead of other competitors, which focus on specific tasks, not the finished product.